Total Payments
$19,663
2024 Payments
$818.69
Companies
41
Transactions
188
Medicare Patients
993
Medicare Billing
$115,238
Payment Breakdown by Category
Other$13,049 (66.4%)
Food & Beverage$3,436 (17.5%)
Research$2,000 (10.2%)
Travel$1,101 (5.6%)
Education$77.98 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,049 | 11 | 66.4% |
| Food and Beverage | $3,436 | 167 | 17.5% |
| Unspecified | $2,000 | 2 | 10.2% |
| Travel and Lodging | $1,101 | 6 | 5.6% |
| Education | $77.98 | 2 | 0.4% |
Payments by Type
General
$17,663
186 transactions
Research
$2,000
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| UCB, Inc. | $10,788 | 23 | $0 (2019) |
| Eisai Inc. | $3,011 | 14 | $0 (2024) |
| Arbor Pharmaceuticals, Inc. | $2,025 | 4 | $0 (2020) |
| LivaNova USA, Inc. | $1,638 | 24 | $0 (2019) |
| JAZZ PHARMACEUTICALS INC. | $363.88 | 21 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $217.01 | 11 | $0 (2018) |
| Lilly USA, LLC | $145.37 | 8 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $122.63 | 4 | $0 (2024) |
| HARMONY BIOSCIENCES LLC | $120.56 | 3 | $0 (2024) |
| Axsome Therapeutics, Inc. | $111.45 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $818.69 | 35 | Neurocrine Biosciences, Inc. ($122.63) |
| 2023 | $262.01 | 11 | Harmony Biosciences LLC ($90.29) |
| 2021 | $52.47 | 7 | GE HEALTHCARE ($52.47) |
| 2020 | $2,059 | 8 | Arbor Pharmaceuticals, Inc. ($2,000) |
| 2019 | $366.30 | 22 | JAZZ PHARMACEUTICALS INC. ($109.01) |
| 2018 | $2,387 | 56 | LivaNova USA, Inc. ($1,495) |
| 2017 | $13,718 | 49 | UCB, Inc. ($10,661) |
All Payment Transactions
188 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Biogen, Inc. | LEQEMBI (Drug) | Food and Beverage | In-kind items and services | $23.11 | General |
| Category: Neurology | ||||||
| 12/04/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $19.52 | General |
| Category: Neuroscience | ||||||
| 11/27/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $31.91 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 11/14/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: NEUROLOGY | ||||||
| 11/05/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $32.48 | General |
| Category: Immunology | ||||||
| 10/30/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $23.20 | General |
| Category: NEUROLOGY | ||||||
| 10/25/2024 | Avadel CNS Pharmaceuticals, LLC | LUMRYZ (Drug) | Food and Beverage | In-kind items and services | $17.69 | General |
| Category: CENTRAL NERVOUS SYSTEM CNS NEUROLOGY | ||||||
| 10/21/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $31.34 | General |
| Category: Neuropsychiatry | ||||||
| 10/18/2024 | Axsome Therapeutics, Inc. | Sunosi (Drug) | Food and Beverage | In-kind items and services | $20.77 | General |
| Category: Neurology | ||||||
| 10/07/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $24.54 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/03/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $20.90 | General |
| Category: Neuroscience | ||||||
| 08/27/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $19.44 | General |
| Category: Neuroscience | ||||||
| 08/19/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $17.41 | General |
| Category: Respiratory | ||||||
| 07/30/2024 | Lilly USA, LLC | AMYVID (Drug) | Food and Beverage | In-kind items and services | $22.85 | General |
| Category: Neuroscience | ||||||
| 07/25/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $29.94 | General |
| Category: NEUROSCIENCE | ||||||
| 07/24/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $21.99 | General |
| Category: NEUROLOGY | ||||||
| 07/16/2024 | Baxter Healthcare | Hillrom - Vest System Model 105 Home Care (Device) | Food and Beverage | In-kind items and services | $27.62 | General |
| Category: Airway Clearance Device | ||||||
| 07/02/2024 | Philips North America LLC | (AK6) Vest Therapy (Device) | Food and Beverage | Cash or cash equivalent | $15.32 | General |
| Category: Medical Device | ||||||
| 06/27/2024 | Axsome Therapeutics, Inc. | Sunosi (Drug) | Food and Beverage | In-kind items and services | $24.59 | General |
| Category: Neurology | ||||||
| 06/20/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $20.40 | General |
| Category: NEUROSCIENCE | ||||||
| 06/18/2024 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $22.92 | General |
| Category: Pulmonology | ||||||
| 06/13/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $32.44 | General |
| Category: NEUROSCIENCE | ||||||
| 06/06/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $29.09 | General |
| Category: Neuropsychiatry | ||||||
| 06/04/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $21.69 | General |
| Category: Neurology | ||||||
| 06/03/2024 | Lilly USA, LLC | AMYVID (Drug) | Food and Beverage | In-kind items and services | $13.49 | General |
| Category: Neuroscience | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| XP109, A Multicenter, Double-Blind, Placebo Controlled, Parallel Group, Efficacy and Safety Evaluation of HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) in Adolescents Aged 13 to 17 Years Old with Moderate-to-Severe Primary Restless Legs Syndrome | Arbor Pharmaceuticals, Inc. | $1,000 | 1 |
| XP110, A Multicenter Open-Label Extension Study to Evaluate the Efficacy and Safety of HORIZANT (Gabapentin Enacarbil) Extended-Release Tablets in Adolescents Aged 13 to 17 Years Old with Moderate-to-Severe Primary Restless Legs Syndrome | Arbor Pharmaceuticals, Inc. | $1,000 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 323 | 355 | $94,801 | $39,278 |
| 2022 | 8 | 216 | 249 | $52,823 | $16,752 |
| 2021 | 9 | 279 | 295 | $78,575 | $30,894 |
| 2020 | 6 | 175 | 195 | $74,990 | $28,314 |
Total Patients
993
Total Services
1,094
Medicare Billing
$115,238
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 75 | 75 | $22,875 | $9,081 | 39.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 41 | 41 | $15,785 | $6,716 | 42.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 32 | 41 | $11,070 | $5,544 | 50.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 42 | 54 | $10,800 | $5,102 | 47.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 49 | 51 | $13,515 | $4,984 | 36.9% |
| 95810 | Sleep study in sleep lab (6 years or older) | Facility | 2023 | 30 | 30 | $7,020 | $2,585 | 36.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 25 | 33 | $4,620 | $1,973 | 42.7% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Facility | 2023 | 17 | 18 | $4,436 | $1,695 | 38.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 12 | 12 | $4,680 | $1,597 | 34.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 37 | 37 | $9,096 | $3,616 | 39.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 23 | 23 | $10,391 | $3,288 | 31.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 48 | 54 | $13,181 | $2,829 | 21.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 25 | 32 | $6,091 | $2,513 | 41.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 31 | 45 | $5,808 | $2,403 | 41.4% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 30 | 36 | $3,406 | $1,076 | 31.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 11 | 11 | $4,059 | $852.31 | 21.0% |
| Q3014 | Telehealth originating site facility fee | Office | 2022 | 11 | 11 | $790.90 | $174.60 | 22.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 89 | 98 | $19,869 | $8,280 | 41.7% |
| 95810 | Sleep monitoring of patient (6 years or older) in sleep lab | Office | 2021 | 16 | 16 | $19,122 | $7,716 | 40.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 30 | 30 | $10,074 | $3,415 | 33.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 20 | 20 | $6,409 | $2,754 | 43.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 22 | 22 | $5,353 | $2,355 | 44.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 16 | 16 | $4,338 | $1,723 | 39.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 27 | 27 | $3,930 | $1,659 | 42.2% |
| 95806 | Unattended sleep study with recording of heart rate, oxygen, respiratory airflow and effort | Office | 2021 | 15 | 15 | $4,670 | $1,188 | 25.4% |
About Dr. Kenneth Murray, MD
Dr. Kenneth Murray, MD is a Sleep Medicine healthcare provider based in Cullman, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1265594733.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kenneth Murray, MD has received a total of $19,663 in payments from pharmaceutical and medical device companies, with $818.69 received in 2024. These payments were reported across 188 transactions from 41 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($13,049).
As a Medicare-enrolled provider, Murray has provided services to 993 Medicare beneficiaries, totaling 1,094 services with total Medicare billing of $115,238. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Sleep Medicine
- Other Specialties Neurology, Neurology
- Location Cullman, AL
- Active Since 12/14/2006
- Last Updated 04/08/2025
- Taxonomy Code 2084S0012X
- Entity Type Individual
- NPI Number 1265594733
Products in Payments
- Briviact (Drug) $10,706
- Banzel (Drug) $2,590
- Horizant (Drug) $2,025
- VNS Therapy (Device) $1,678
- Fycompa (Drug) $357.11
- INGREZZA (Drug) $122.63
- Xyrem (Drug) $120.76
- WAKIX (Drug) $120.56
- XYWAV (Drug) $114.44
- Sunosi (Drug) $111.45
- AMYVID (Drug) $85.51
- Neupro (Drug) $81.99
- COPAXONE (Drug) $71.12
- XYREM (Drug) $65.90
- LYRICA (Drug) $65.87
- AUSTEDO (Drug) $65.20
- SUNOSI (Drug) $62.78
- QULIPTA (Drug) $62.38
- KISUNLA (Drug) $59.86
- APTIOM (Drug) $57.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.